Research
Hormonal
Pharmacological agents like liraglutide and dual agonists contribute to weight loss by retarding gastric emptying.
Incorporating GLP-1 agonists may enhance weight loss strategies.
StrongSupportsmedium confidence
Indeed, these effects provide the basis for the association of altered gastric emptying in the appetite and weight loss responses to pharmacological interventions particularly by those acting on receptors of incretin agonists such as liraglutide and the dual agonists, tirzepatide and cotadutide, all of which retard gastric emptying.
Why this rating
The review discusses established pharmacological effects based on existing studies.
Source
The role of gastric function in control of food intake (and body weight) in relation to obesity, as well as pharmacological and surgical interventions
Michael Camilleri · Neurogastroenterology & Motility · 2023
DOI 10.1111/nmo.14660
reviewCited 14×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →